Improving MRI to better understand cancer metabolism
Plug-and-play Hyperpolarized MRI of Metabolism on Clinical Scanners
['FUNDING_R01'] · MASSACHUSETTS GENERAL HOSPITAL · NIH-11012301
This study is looking at a new way to use MRI scans to see how a substance called pyruvate is used in the body, especially in cancer patients, to help doctors better understand cancer and how well treatments are working.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | MASSACHUSETTS GENERAL HOSPITAL (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-11012301 on ClinicalTrials.gov |
What this research studies
This research focuses on enhancing MRI technology to track how pyruvate, a key metabolite, is processed in the body, particularly in cancer patients. By using hyperpolarized MRI techniques, the study aims to increase the sensitivity of MRI scans, allowing for better detection of metabolic changes associated with cancer. Patients will receive injections of hyperpolarized 13C-pyruvate, and the resulting metabolic transformations will be monitored in real-time. This approach could provide valuable insights into cancer biology and treatment responses.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with various types of cancer who are undergoing treatment.
Not a fit: Patients with non-cancerous conditions or those who are not undergoing any form of cancer treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more accurate diagnoses and treatment monitoring for cancer patients.
How similar studies have performed: Previous research has shown promising results using hyperpolarized MRI techniques in cancer metabolism, indicating potential for success in this approach.
Where this research is happening
BOSTON, UNITED STATES
- MASSACHUSETTS GENERAL HOSPITAL — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ROSEN, MATTHEW SCOT — MASSACHUSETTS GENERAL HOSPITAL
- Study coordinator: ROSEN, MATTHEW SCOT
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer therapy, Breast Cancer